Table 2.
Hormone levels by treatment assignment at baseline and month 48 in KEEPS participants who were compliant to treatment.
| Treatment | Baseline | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| FSH (IU/l) | LH (IU/l) | Testosterone (ng/dl) | Estrone (pg/ml) | Estradiol (pg/ml) | ||||||
| Mean (SD) | Med (IQR) | Mean (SD) | Med (IQR) | Mean (SD) | Med (IQR) | Mean (SD) | Med (IQR) | Mean (SD) | Med (IQR) | |
| Placebo (n=148) | 84.1 (34) | 79.2 (50.0) | 38.8 (16) | 36.7 (21.9) | 17.1 (11) | 15.0 (9.0) | 35.3 (27) | 28.0 (17.0) | 18.7 (38) | 7.0 (7.0) |
| tE2 (n=107) | 94.1 (41) | 88.4 (50.5) | 42.0 (16) | 40.9 (20.3) | 16.6 (8) | 15.0 (9.0) | 32.3 (21) | 26.0 (20.0) | 18.2 (32) | 6.8 (5.4) |
| oCEE (n=109) | 92.2 (34) | 86.2 (46.2) | 41.1 (15) | 40.0 (20.3) | 17.6 (10) | 17.0 (9.0) | 33.3 (18) | 28.0 (20.5) | 13.8 (21) | 6.5 (7.0) |
| Month 48 | ||||||||||
| Placebo (n=148) | 84.6 (33) | 80.0 (47.1) | 38.5 (13) | 31.75 (15.6) | 18.1 (18) | 15.0 (10) | 28.5 (11) | 28.0 (15.0) | 7.2 (4) | 6.6 (4.0) |
| tE2 (n=107) | 65.2 (30) | 60.5 (41.6) | 31.2 (11) | 31.3 (15.0) | 17.0 (9) | 15.0 (10.0) | 52.4 (26) | 50.0 (35.0) | 47.1 (40) | 41 (53.7) |
| oCEE (n=109) | 69.5 (29) | 68.0 (39.4) | 35.6 (14) | 31.8 (20.6) | 20.4 (10) | 18.0 (12.0) | 106.2 (86) | 88.0 (90.0) | 15.5 (10) | 13.0 (12.3) |
tE2, transdermal estradiol; oCEE, oral conjugated equine estrogens; FSH, follicle stimulating hormone; LH, luteinizing hormone; SD, standard deviation; Med, Median; IQR, interquartile range.